KTTA ▲ +3.8% - Pasithea Therapeutics Corp. $KTTA KTTAW - Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference Pasithea Therapeutics shares rose 3.8% following the company's announcement of initial clinical data from its PAS-004 trial in neurofibromatosis type 1 patients, which will be presented at the 2026 European Neurofibromatosis Conference. The disclosure of early-stage trial results typically generates investor interest in clinical-stage biotech companies, particularly when emerging data is presented at major medical conferences. 14-SEP-2026 07:01 AM ET